Anticancer agent 319
Anticancer agent 319 is an anticancer agent. Anticancer agent 319 inhibits the proliferation of liver cancer cells. Anticancer agent 319 inhibits AKT phosphorylation and blocks the PI3K/AKT signaling axis; meanwhile, it inhibits ERK1/2 phosphorylation and blocks the MAPK/ERK signaling axis. Anticancer agent 319 induces G2/M phase cell cycle arrest, triggers apoptosis, and reduces mitochondrial membrane potential in liver cancer cells. Anticancer agent 319 can be used for the research of hepatocellular carcinoma.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Formule: C33H34Cl2N2O8
- Masse moléculaire:657.54
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
Anticancer agent 319 (Compound 11e) (48-72 h) potently inhibits the proliferation of human hepatocellular carcinoma cells HepG2 and Hep3B, with IC50 values of 2.22 μM (72 h, HepG2), 4.55 μM (48 h, HepG2) and 4.95 μM (48 h, Hep3B), respectively, but exerts no inhibitory effect on the proliferation of Huh-7 cells[1].
Anticancer agent 319 (2.5-10 μM; 24-48 h) inhibits the migration of human hepatocellular carcinoma cell line HepG2 in a dose-dependent manner[1].
Anticancer agent 319 (2.5-10 μM; 36-48 h) induces G2/M cell cycle arrest, triggers concentration-dependent apoptosis, and reduces mitochondrial membrane potential in human hepatocellular carcinoma HepG2 cells[1].
Anticancer agent 319 (2.5-10 μM; 36 h) dose-dependently inhibits the phosphorylation of AKT (Ser473) and ERK1/2 (Thr202/Tyr204), and blocks the PI3K/AKT and MAPK/ERK signaling axes in human hepatocellular carcinoma HepG2 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:human hepatocellular carcinoma HepG2 cells
-
Concentration:2.5, 5 and 10 μM
-
Incubation Time:24 h; 48 h
-
Result:Inhibited HepG2 cell migration in a dose-dependent manner.
Reduced the wound closure rate to 52.96% (2.5 μM), 27.41% (5 μM), and 13.45% (10 μM) after 48 h, compared to 59.11% in the control group.
-
Cell Line:human hepatocellular carcinoma HepG2 cells
-
Concentration:2.5, 5 and 10 μM
-
Incubation Time:36 h
-
Result:Induced G2/M phase arrest at all concentrations.
Increased the SubG1 (apoptotic) population to approximately 22.33% at 5 μM and 10 μM, indicating DNA fragmentation and apoptosis.
-
Cell Line:human hepatocellular carcinoma HepG2 cells
-
Concentration:2.5, 5 and 10 μM
-
Incubation Time:48 h
-
Result:Induced characteristic apoptotic nuclear changes, including condensation and fragmentation, in a dose-dependent manner.
Control cells showed uniform, pale blue nuclear staining.\nIncreased the proportion of both early and late apoptotic cells in a concentration-dependent manner.
Caused significant reductions in viable cells compared to the control.
-
Cell Line:human hepatocellular carcinoma HepG2 cells
-
Concentration:2.5, 5 and 10 μM
-
Incubation Time:36 h
-
Result:Dose-dependently inhibited the phosphorylation of AKT (Ser473) and ERK1/2 (Thr202/Tyr204).
Nearly completely suppressed phosphorylation at the highest concentration.
Chemical Information
-
Masse moléculaire 657.54
-
Formule C33H34Cl2N2O8
-
SMILES
COC([C@@H](NC(CCC(OCCOC1=CC2=C(C3=CC=CC=C3C(O2)=O)C=C1)=O)=O)CC4=CC=C(C=C4)N(CCCl)CCCl)=O
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Anticancer agent 319 Related Classifications
HY-183316 Related Classifications
Powered by Bioz